Loading stock data…
Cryoport (CYRX)
$15.47-0.34 (-2.15%)
Market ClosedLast close Sep 8
Cryoport, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cryoport, Inc. in the Industrials sector is trading at $15.47 with a market capitalization of $741M. Wall Street consensus targets $19.33 (9 analysts), implying a +25.0% move over the next 12 months. The stock is currently near its 52-week high of $17.20, remaining 30.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +25.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $47.80M↑ | $45.45M↑ | $44.23M↓ | $45.45M↑ | $41.04M |
| Gross Profit | $21.91M↑ | $21.71M↑ | $21.32M↓ | $21.38M↑ | $18.64M |
| Operating Income | -$9.61M↑ | -$10.03M↓ | -$9.93M↓ | -$9.65M↓ | -$7.19M |
| Net Income | -$10.54M↑ | -$11.64M↓ | -$6.94M↓ | $105.18M↑ | -$11.98M |
Peer Comparison
Fundamentals
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostora...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$741.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.36%
Volume
Today's trading volume
542,990
Recent News
Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions
The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s Cell and Gene Therapy logistics and bioservices as key supports for the higher target range. As you read on, you will see how to track these shifting assumptions and what they might mean for your own...
Cryoport (CYRX) Q2 2026 Earnings Call Transcript
CGT services revenue surged 15% as clinical trial support expanded to 779 trials globally.
CryoPort (CYRX) Upgraded to Buy: Here's Why
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investor Confidence in CryoPort (CYRX) Strengthened Backed by Pipeline Expansion
Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]
Cryoport, Inc. Q2 2026 Earnings Call Summary
Moby summary of Cryoport, Inc.'s Q2 2026 earnings call